InsiderTrades.com logo
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
From InvestorPlace   |   Ad
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Click here now to watch the full briefing and discover the steps to take today.

BTTX Insider Trading

Insider Ownership Percentage: 51.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Better Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Better Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Better Therapeutics Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 11/21/2024 01:00 AM ET

This chart shows the closing price history over time for BTTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Democrats Sold Out the American Dream - Are you ready?
From Behind the Markets   |   Ad
There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters."
Click here to see exactly what you need to do >>>

Better Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2023Andrew J. ArmaninoDirectorBuy274,010$0.73$200,027.30728,368View SEC Filing Icon  
7/27/2023David P PerryChairmanBuy1,233,045$0.73$900,122.8513,030,393View SEC Filing Icon  
7/27/2023Frank KarbeCEOBuy137,005$0.73$100,013.65429,429View SEC Filing Icon  
7/27/2023Mark A BermanInsiderBuy54,802$0.73$40,005.46388,191View SEC Filing Icon  
5/16/2023Elder GrangerDirectorBuy600$0.87$522.001,600View SEC Filing Icon  
4/10/2023Frank KarbeInsiderBuy242,424$0.82$198,787.68292,424View SEC Filing Icon  
4/10/2023Geoffrey M ParkerDirectorBuy303,030$0.82$248,484.60343,030View SEC Filing Icon  
9/15/2022Frank KarbeInsiderBuy50,000$2.09$104,500.0050,000View SEC Filing Icon  
9/12/2022Mark HeinenInsiderBuy23,868$1.94$46,303.9243,868View SEC Filing Icon  
6/24/2022Mark HeinenInsiderBuy2,281$1.75$3,991.752,281View SEC Filing Icon  
6/13/2022Geoffrey M ParkerDirectorBuy25,000$1.45$36,250.0040,000View SEC Filing Icon  
6/10/2022Mark HeinenInsiderBuy5,000$1.56$7,800.0020,000View SEC Filing Icon  
3/31/2022Kevin J. AppelbaumCEOBuy2,500$1.97$4,925.006,250View SEC Filing Icon  
3/31/2022Mark HeinenInsiderBuy5,000$1.98$9,900.0015,000View SEC Filing Icon  
3/29/2022Andrew J. ArmaninoDirectorBuy40,000$2.14$85,600.00View SEC Filing Icon  
12/21/2021Risa J. Lavizzo-MoureyDirectorBuy10,000$4.60$46,000.00View SEC Filing Icon  
12/20/2021Kevin J. AppelbaumCEOBuy1,000$4.60$4,600.00View SEC Filing Icon  
12/15/2021Kevin J. AppelbaumCEOBuy750$4.71$3,532.50View SEC Filing Icon  
12/15/2021Mark HeinenInsiderBuy2,333$4.70$10,965.10View SEC Filing Icon  
12/13/2021Andrew J. ArmaninoDirectorBuy21,000$5.48$115,080.00View SEC Filing Icon  
12/13/2021Mark HeinenInsiderBuy500$5.45$2,725.00View SEC Filing Icon  
12/10/2021Kevin J. AppelbaumCEOBuy1,000$5.98$5,980.00View SEC Filing Icon  
12/3/2021Elder GrangerDirectorBuy1,000$6.66$6,660.00View SEC Filing Icon  
12/2/2021Kevin J. AppelbaumCEOBuy500$6.84$3,420.00View SEC Filing Icon  
11/29/2021Andrew J. ArmaninoDirectorBuy17,000$6.96$118,320.00View SEC Filing Icon  
See Full Table
What This Post-Election Shift Means for Your Investments
From InvestorPlace   |   Ad
The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.
Click here now to watch the full briefing and prepare for what's next.

SEC Filings (Institutional Ownership Changes) for Better Therapeutics (NASDAQ:BTTX)

34.00% of Better Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BTTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Better Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/12/2024MMCAP International Inc. SPC356,270$65K0.0%-77.5%0.715%Search for SEC Filing on Google Icon
11/14/2023MMCAP International Inc. SPC1,583,079$0.58M0.2%N/A3.340%Search for SEC Filing on Google Icon
5/15/2023Farallon Capital Management LLC699,042$0.51M0.0%-14.1%2.931%Search for SEC Filing on Google Icon
5/10/2022Sectoral Asset Management Inc.878,531$1.74M0.3%-9.8%3.721%Search for SEC Filing on Google Icon
5/4/2022Victory Capital Management Inc.272,720$0.54M0.0%N/A1.155%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Better Therapeutics logo
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Read More on Better Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

2,000 shs

Average Volume

2,449,991 shs

Market Capitalization

$5,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Who are the company insiders with the largest holdings of Better Therapeutics?

Better Therapeutics' top insider shareholders include:
  1. David P Perry (Chairman)
  2. Andrew J Armanino (Director)
  3. Frank Karbe (CEO)
  4. Mark A Berman (Insider)
  5. Geoffrey M Parker (Director)
  6. Frank Karbe (Insider)
  7. Elder Granger (Director)
Learn More about top insider investors at Better Therapeutics.
What This Post-Election Shift Means for Your Investments
From InvestorPlace   |   Ad
The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.
Click here now to watch the full briefing and prepare for what's next.